CVR 70996510Private limited company (ApS)Engroshandel med andre fødevarer (463800)Sadelmagervej 30, 7100 VejleFounded 19 Nov 1982
Compare withsimilar companiesanother companyits industry
PHARMA NORD EXPORT ApS
CVR holds no employment figures for this company.
The newest trades with a company on a side are on the latest property trades.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Cite as: PHARMA NORD EXPORT ApS, https://dandex.ai/company/70996510/pharma-nord-export. Source: Dandex, from CVR, read 22 Nov 2026.
Dandex is Danish Company Data. Connect it once and ask about PHARMA NORD EXPORT ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Dandex has an MCP server at https://dandex.ai/mcp and a REST API at https://dandex.ai/api/v1.
Set up DandexEmployees
66
Annual report 2025, average
Gross profit
37.7M
DKK, group, annual report 2025
+7.7% on 2024
Result
+11.6M
DKK, group, annual report 2025
Equity
47M
DKK, group, annual report 2025
PHARMCO II ApSCVR 25202899, 50% to under 66.7% of capital and votes
PharmCo III ApSCVR 41103647, 33.3% to under 50% of capital and votes
Operating company
Dandex estimate: revenue or gross profit in the 2025 reportEli Wallinsince 19 Nov 1982
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 2520289950% to under 66.7% of capital and votesclass A,Bnotified 12 Oct 2018since 4 Feb 2000
CVR 4110364733.3% to under 50% of capital and votesclass A, Bsince 28 Jan 2020
33.3% to under 50% of capital and votesclass A,Bnotified 12 Oct 20184 Feb 2000 to 28 Jan 2020
Ultimate controller
Holding in PHARMCO II ApS, since 4 Feb 2000
Holding company
CVR 25202899Private limited company (ApS)
Holding in PHARMA NORD EXPORT ApS, since 4 Feb 2000
This company
PHARMA NORD EXPORT ApS
CVR 70996510
3 Danish companies.
SubsidiaryCVR 15183381100% of capital and votes
SubsidiaryCVR 13914435100% of capital and votes
SubsidiaryCVR 2867052466.7% to under 90% of capital and votes
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR. Subsidiary (datterselskab): 50% or more of the votes, a Dandex estimate; in the 50% band a joint venture is not ruled out.
Group figures (koncern), in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit 37.7M, Operating profit 18.7M, Result for the year 11.6M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 132.1M, Equity 47M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | 26,012 | 26,460 | 32,656 | 35,054 | 37,743 |
| Operating profit | +3,416 | +4,566 | +9,222 | +10,521 | +18,748 |
| Result for the year | +3,188 | +2,130 | +6,351 | +6,881 | +11,583 |
| Equity | 44,001 | 46,117 | 37,487 | 44,304 | 47,045 |
| Total assets | 116,326 | 102,453 | 86,374 | 108,962 | 132,057 |
| Employees (average) | 49 | 63 | 65 | 77 | 66 |
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseBonus issue from reserves | None | None | None | 200,000 | |
| IncreaseBonus issue from reserves | None | None | None | 80,000 | |
| FoundingNot read from the announcement | None | None | None | 30,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
Group figures (koncern), in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit growth (vækst i bruttofortjeneste) | 3.8% | 1.7% | 23.4% | 7.3% | 7.7% |
| EBITDA | 4,627 | 5,765 | 10,475 | 12,006 | 19,829 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | 2.1% | 28.6% | 3.2% | 18.5% | -14.3% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 1,033 | 844 | 685 | 10,445 | 1,061 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Source: CVR, read 22 Nov 2026.
17 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Bestyrelse:
Fratrådte:
Sven Moesgaard, den 30.05.2025.
Direktion:
Fratrådte:
Sven Moesgaard, den 14.12.2020.
Vedtægter ændret: 29.05.2020
Direktion:
Fratrådte:
Eli Wallin, den 29.05.2020.
Tiltrådte:
Eli Wallin, (adm. dir), den 29.05.2020.
Selskabet tegnes af den samlede bestyrelse, af den samlede direktion eller af den administrerendedirektør.
Vedtægter ændret:
25.11.2010.
Regnskabsår ændret til:
01.01 - 31.12.
Omlægningsperiode:
01.05.2010 - 31.12.2010.
Vedtægter ændret:
04.11.2009.
Bestyrelse:
Indtrådt i bestyrelsen:
Advokat Michael Christiani Havemann (formand), den 04.11.2009, Direktør Claus Hancke, den 04.11.2009.
Selskabet tegnes af den samlede bestyrelse eller den samlede direktion.
Revision:
Udtrådt af revisionen:
H. MARTINSEN, STATSAUTORISERET REVISIONSAKTIESELSKAB, den 21.10.2009.
Indtrådt i revisionen:
CVR-NR. 32285201 MARTINSEN STATSAUTORISERET REVISIONSPARTNERSELSKAB, Gunhilds Plads 2, 7100 Vejle, den 21.10.2009.
Ved kommunalreformen den 1. januar 2007 er hjemstedskommunen ændret.
Revision:
Udtrådt af revisionen:
CVR-NR. 13909407 REVISIONSFIRMAET H. MARTINSEN A/S, den 01.01.2006.
Indtrådt i revisionen:
H. MARTINSEN, STATSAUTORISERET REVISIONSAKTIESELSKAB, Gunhilds Plads 2, 7100 Vejle, den 01.01.2006.
Vedtægter ændret:
13.12.1996.
Kapitalforhøjelse:
kr. 120.000,00 indbetalt ved overførte reserver / overskud, kurs 100,00,
Klasser:
A kr. 15.000,00, B kr. 105.000,00.
Kapitalen udgør herefter kr. 200.000,00.
Kapitalen er opdelt i klasser:
A kr. 25.000,00, B kr. 175.000,00.
Direktion:
Indtrådt i direktionen:
Direktør Sven Moesgaard.
Revision:
Udtrådt af revisionen:
MVN Revision
Indtrådt i revisionen:
REVISIONSFIRMAET H. MARTINSEN A/S, Jernbanegade 54, 6000 Kolding
Vedtægter ændret:
06.09.1988
Slettede binavne:
TSA DANMARK ApS (PHARMA NORD EXPORT ApS) TRAUDE SCHNEIDER ASTROFAKTA-DANMARK ApS (PHARMA NORD EXPORT ApS)
Vedtægter ændret:
08.12.1987
Nyt navn:
PHARMA NORD EXPORT ApS
Nye binavne:
TSA DANMARK ApS (PHARMA NORD EXPORT ApS) TRAUDE SCHNEIDER ASTROFAKTA-DANMARK ApS (PHARMA NORD EXPORT ApS)
Slettet binavn: TAS-DANMARK ApS (TRAUDE SCHNEIDER ASTROFAKTA-DANMARK ApS)
Ny adresse:
Jellingvej 9, 7100 Vejle
Kapitalforhøjelse:
kr. 50.000,00 indbetalt ved fonds, kurs 100,0,
Klasser:
A kr. 5.000,00, B kr. 45.000,00
Kapitalen udgør herefter kr. 80.000,00
Kapitalen er opdelt i klasser:
A kr. 10.000,00, B kr. 70.000,00
Bestyrelse:
Udtrådt af bestyrelsen:
Vedrørende den under 16.03.1988 registrerede ændring for
REG.NR. ApS51985 PHARMA NORD EXPORT ApS meddeles, at kapitalforhøjelsen på kr. 50.000,- er sket ved kontant indbetaling kurs 100 (fejlagtigt registreret som indbetalt ved fondanparter kurs 100)
Binavn:
TAS-DANMARK ApS (TRAUDE SCHNEIDER ASTROFAKTA-DANMARK ApS)
Stiftelsesdato:
19.11.1982
Seneste vedtægtsdato:
17.08.1984
Kapital:
kr. 30.000,00
Kapitalen er opdelt i klasser:
A kr. 5.000,00, B kr. 25.000,00
Indbetalingsmåde:
kontant/i værdier kr. 30.000,00 til kurs 100,0
Bestyrelse:
Hans John Bornemark, Sven Moesgaard, Bernd Schneider, Direktør Eli Wallin
Direktion:
Direktør Eli Wallin
Selskabet tegnes af et medlem af bestyrelsen
i forening med en direktør eller af den
samlede bestyrelse
Revision:
MVN Revision, 6000 Kolding
Første regnskabsår:
19.11.1982 - 30.04.1984
Regnskabsår:
01.05 - 30.04
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 22 Nov 2026.
What Pro holds for PHARMA NORD EXPORT ApS:
Have Pro? Sign in.
P-number 1013450958Tinglykke 4, 6500 Vojens
P-number 1002333001Sadelmagervej 30, 7100 Vejle